Multiple Myeloma Treatment in India
Get Multiple Myeloma Treatment at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Multiple Myeloma Treatment in UAE
Multiple Myeloma Treatment at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Multiple Myeloma is a malignancy of plasma cells in the bone marrow, and modern treatment protocols — including VRd (Bortezomib, Lenalidomide, Dexamethasone) induction, Autologous Stem Cell Transplantation (ASCT), and Daratumumab-based regimens — have transformed it from a rapidly fatal disease into a manageable, often remission-sustaining condition, with 5-year survival rates exceeding 55–60% in transplant-eligible patients at high-volume centers. International patients travel to India and the UAE with GAF Healthcare to access these globally benchmarked protocols at a fraction of Western costs, supported by dedicated oncology teams, JCI/NABH-accredited institutions, and end-to-end medical concierge services.
Hospital Stay: 21–45 days (ASCT phase requires 3–4 weeks inpatient; induction cycles are outpatient-based but require local stay) • Total Stay in Country (Fit-to-Fly): 8–14 weeks from start of induction to safe air travel post-ASCT engraftment; induction-only patients may fly after 4–6 weeks • Success Rate: 55–65% 5-year overall survival in transplant-eligible patients; Complete Response (CR) rates of 30–45% with VRd induction; ≥Very Good Partial Response (VGPR) rates of 70–80% with Daratumumab-VRd quadruplet therapy
What Is It?
Multiple Myeloma (MM) is a clonal plasma cell neoplasm in which malignant plasma cells proliferate within the bone marrow, crowding out normal hematopoietic cells and producing dysfunctional monoclonal immunoglobulins (M-protein or paraprotein). This pathological cascade results in the hallmark CRAB criteria: hyperCalcemia, Renal insufficiency (from cast nephropathy and light-chain deposition), Anemia (normocytic, normochromic due to marrow infiltration), and Bone lesions (osteolytic lesions driven by RANKL-mediated osteoclast activation and suppressed osteoblast activity). Beyond CRAB features, patients frequently present with recurrent infections due to humoral immunosuppression, peripheral neuropathy, and fatigue. The disease is staged using the Revised International Staging System (R-ISS), which integrates serum beta-2 microglobulin, albumin, LDH, and cytogenetic risk markers such as del(17p), t(4;14), and t(14;16) — high-risk cytogenetics that directly inform treatment intensity.
The contemporary standard of care for newly diagnosed MM (NDMM) is risk-stratified and transplant-eligibility-dependent. For transplant-eligible patients (typically age <70 with adequate organ function), the globally accepted approach is: (1) VRd induction for 3–4 cycles, (2) peripheral blood stem cell mobilization and apheresis, (3) high-dose Melphalan (HDM 200 mg/m²) conditioning followed by Autologous Stem Cell Transplantation (ASCT), and (4) lenalidomide-based maintenance therapy. The addition of Daratumumab (an anti-CD38 monoclonal antibody) to VRd — creating the quadruplet regimen Dara-VRd — has been validated by the GRIFFIN and PERSEUS trials, demonstrating significantly deeper MRD (Minimal Residual Disease) negativity rates and improved progression-free survival. For transplant-ineligible patients, Daratumumab-based triplet regimens (Dara-Rd or Dara-VMP) are the standard of care, as established by the MAIA and ALCYONE trials.
India and the UAE have emerged as premier destinations for MM treatment because both ecosystems offer access to these exact protocols — including next-generation immunotherapy, CAR-T cell therapy at select centers, and MRD testing by flow cytometry or NGS — with oncology teams trained at international institutions. India's high patient volume translates into exceptional procedural expertise, particularly in ASCT, where centers perform hundreds of transplants annually. The UAE provides premium clinical environments, proximity for patients from the Middle East and Africa, and access to novel clinical trials through its JCI-accredited academic medical centers in Dubai and Abu Dhabi.
Candidates
• ELIGIBILITY FOR TRANSPLANT-ELIGIBLE PATHWAY (VRd → ASCT → Maintenance):
• Age typically ≤70 years (physiological age assessed over chronological age; fit patients up to 75 may qualify after geriatric oncology evaluation)
• Confirmed diagnosis of symptomatic Multiple Myeloma per IMWG 2014 criteria (presence of CRAB criteria or SLiM criteria: ≥60% clonal plasma cells, sFLC ratio ≥100, >1 focal lesion on MRI)
• ECOG Performance Status 0–2
• Adequate cardiac function: LVEF ≥45% on Echocardiogram (ECHO) — essential prior to high-dose Melphalan conditioning
• Adequate pulmonary function: DLCO ≥50% predicted (Pulmonary Function Tests required)
• Adequate renal function: Creatinine Clearance ≥30 mL/min (CrCl <30 may still be considered with dose-adjusted regimens at specialized centers)
• No uncontrolled active infection or uncontrolled systemic comorbidities
• REQUIRED DIAGNOSTIC WORKUP BEFORE TREATMENT:
• Bone Marrow Biopsy and Aspirate with immunohistochemistry (IHC) and flow cytometry (minimum 8-color panel for plasma cell phenotyping)
• Cytogenetic analysis: FISH panel for del(17p), t(4;14), t(14;16), t(11;14), gain(1q21) — defines high-risk vs. standard-risk cytogenetics per R-ISS
• Serum Protein Electrophoresis (SPEP) + Immunofixation Electrophoresis (IFE) + 24-hour Urine Protein Electrophoresis (UPEP)
• Serum Free Light Chain (sFLC) assay (Kappa/Lambda ratio)
• Whole-body PET-CT scan or Low-dose Whole-body CT (WBCT) / Whole-body MRI for skeletal survey and extramedullary disease assessment
• MRI Spine (mandatory if cord compression is suspected)
• Complete Blood Count (CBC), Comprehensive Metabolic Panel, Serum LDH, Beta-2 Microglobulin, Serum Albumin (for R-ISS staging)
• Echocardiogram (ECHO) and 12-lead ECG
• Pulmonary Function Tests (PFTs) including DLCO
• HLA typing (if allogeneic SCT is being considered for high-risk/relapsed disease)
• Hepatitis B, C, HIV serology (mandatory before Daratumumab initiation)
• CONTRAINDICATIONS / RELATIVE CONTRAINDICATIONS:
• Active uncontrolled systemic infection (including active TB — must be treated to completion before immunosuppressive therapy)
• Severe cardiac dysfunction (LVEF <35%, uncontrolled arrhythmia, recent MI within 6 months)
• Severe hepatic impairment (Child-Pugh Class C) — limits proteasome inhibitor dosing
• Prior allergic reaction or hypersensitivity to Bortezomib, Lenalidomide, or Daratumumab
• Pregnancy or breastfeeding (Lenalidomide is strictly teratogenic — Category X; mandatory pregnancy testing and dual contraception protocol required)
• Pre-existing severe peripheral neuropathy (Grade 3–4) — relative contraindication to Bortezomib; Carfilzomib substitution considered
• Smoldering (asymptomatic) Myeloma without high-risk features — watch-and-wait approach; not a candidate for immediate systemic therapy
Procedure
INDUCTION THERAPY — VRd (STANDARD TRIPLET) AND DARA-VRd (QUADRUPLET, PREFERRED FOR HIGH-RISK OR FIT PATIENTS):
VRd (Bortezomib 1.3 mg/m² SC on Days 1,4,8,11; Lenalidomide 25 mg PO Days 1–14; Dexamethasone 20 mg PO/IV Days 1,2,4,5,8,9,11,12) administered in 21-day cycles for 3–4 cycles is the internationally accepted backbone induction regimen (established by the SWOG S0777 trial). Subcutaneous Bortezomib administration (vs. IV) is now strongly preferred as it reduces the incidence of peripheral neuropathy from ~16% to ~6% without compromising efficacy. For fit patients with standard or high-risk cytogenetics, the quadruplet Daratumumab-VRd (Dara-VRd) is increasingly the preferred frontline approach, based on the PERSEUS trial showing a 58% reduction in progression or death vs. VRd alone and MRD negativity rates of 75.2% vs. 47.5%. Daratumumab is administered IV (16 mg/kg) or as subcutaneous Daratumumab-hyaluronidase (1800 mg fixed dose, Darzalex Faspro) — SC administration dramatically reduces infusion time from 4–6 hours to 3–5 minutes and lowers infusion-related reaction rates.
STEM CELL MOBILIZATION AND APHERESIS:
Following induction, peripheral blood stem cell (PBSC) mobilization is performed using G-CSF (Filgrastim 10 µg/kg/day SC for 4–5 days) with or without Plerixafor (a CXCR4 antagonist, added in poor mobilizers or as part of a 'just-in-time' strategy). Apheresis is performed via large-bore central venous catheter (or peripheral if veins are adequate), targeting a minimum stem cell harvest of ≥2 × 10⁶ CD34+ cells/kg (ideally ≥4–5 × 10⁶ CD34+ cells/kg to allow tandem ASCT if needed). CD34+ enumeration by flow cytometry guides apheresis endpoint decisions.
AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) — HIGH-DOSE MELPHALAN CONDITIONING:
High-dose Melphalan (Mel-200: 200 mg/m² IV on Day -2 or split over Days -3 and -2) is the global standard conditioning regimen prior to ASCT, providing myeloablation and anti-myeloma cytoreduction. Patients are admitted to a HEPA-filtered, positive-pressure bone marrow transplant unit. Cryopreserved autologous stem cells are reinfused on Day 0. Neutrophil engraftment (ANC >0.5 × 10⁹/L for 3 consecutive days) typically occurs on Days +10 to +14. Platelet engraftment (>20 × 10⁹/L unsupported) follows shortly after. During the aplastic phase (Days 0–14), patients require: prophylactic antibiotics (Fluoroquinolone), antifungals (Fluconazole or Posaconazole), antiviral prophylaxis (Acyclovir), GCSF from Day +5, platelet and red cell transfusion support, and mucositis management (IV nutrition, opioid analgesia, cryotherapy during Melphalan infusion). Tandem ASCT (two sequential transplants) may be offered to high-risk cytogenetic patients (del17p, t(4;14)) who fail to achieve at least VGPR after first ASCT.
POST-TRANSPLANT MAINTENANCE THERAPY:
Lenalidomide maintenance (10 mg PO Days 1–21 of 28-day cycles, escalated to 15 mg if tolerated) is the global standard post-ASCT maintenance, continued until progression or intolerance, based on the CALGB 100104 and IFM 2005-02 trials showing significant improvement in PFS and OS. For high-risk cytogenetics (particularly t(4;14) or del17p), Bortezomib-based maintenance (Bortezomib 1.3 mg/m² SC every 2 weeks) alone or combined with Lenalidomide (VR maintenance) is preferred. Daratumumab maintenance post-ASCT is being studied in the AURIGA trial.
TRANSPLANT-INELIGIBLE PATIENTS — DARA-Rd AND DARA-VMP:
For elderly or comorbid patients ineligible for ASCT, Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) continuous therapy — based on the MAIA trial (mPFS 61.9 months vs. 34.4 months with Rd alone) — is the preferred standard. An alternative is Daratumumab-Bortezomib-Melphalan-Prednisone (Dara-VMP), established by the ALCYONE trial.
RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) OPTIONS AVAILABLE IN INDIA AND UAE:
• Carfilzomib-Lenalidomide-Dexamethasone (KRd) — ASPIRE trial
• Isatuximab (anti-CD38) + Pomalidomide-Dexamethasone (IsaPd) — ICARIA-MM trial
• Elotuzumab (anti-SLAMF7) + Pomalidomide-Dexamethasone — ELOQUENT-3 trial
• Selinexor (XPO1 inhibitor) + Dexamethasone for penta-refractory disease
• Belantamab Mafodotin (anti-BCMA ADC) — available at select centers
• CAR-T Cell Therapy (Idecabtagene Vicleucel / Ide-cel; Ciltacabtagene Autoleucel / Cilta-cel) — available at select tertiary centers in India and UAE with advanced cellular therapy programs
• Bispecific Antibodies (Teclistamab anti-BCMA × CD3; Talquetamab anti-GPRC5D × CD3) — available under compassionate use or clinical trial frameworks
MRD ASSESSMENT — MEASURING DEPTH OF RESPONSE:
Minimal Residual Disease (MRD) negativity is now a critical treatment milestone and surrogate endpoint. MRD is assessed by: (1) Next-Generation Flow Cytometry (NGF) — EuroFlow 8-color panel, sensitivity 10⁻⁵ to 10⁻⁶; (2) Next-Generation Sequencing (NGS) — ClonoSEQ platform, sensitivity 10⁻⁶; (3) PET-CT for extramedullary MRD imaging. Achieving sustained MRD negativity (≥12 months) is associated with significantly prolonged PFS and is increasingly used to guide treatment de-escalation decisions at experienced centers.
Cost of Multiple Myeloma Treatment: India vs. UAE
The total cost of Multiple Myeloma treatment — encompassing VRd or Dara-VRd induction, ASCT, and post-transplant maintenance — varies significantly between India and the UAE, with India offering costs that are typically 50–65% lower than the UAE while maintaining equivalent oncological outcomes at JCI and NABH-accredited transplant centers. The cost ranges below reflect the complete treatment episode including hospitalization, chemotherapy drugs (Bortezomib, Lenalidomide, Daratumumab), high-dose Melphalan conditioning, stem cell processing and cryopreservation, apheresis, BMT unit stay, and standard supportive medications. Drug costs — particularly Daratumumab and novel agents — represent the largest variable cost component and are significantly lower in India due to domestic biosimilar availability and government pricing controls. The UAE costs reflect premium facility standards, imported branded biologics, and higher operational overheads, but offer unmatched infrastructure and proximity for patients from the Middle East and Africa.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $18,000 – $45,000 | ~55% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $45,000 – $95,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-TREATMENT WORKUP AND PLANNING (Weeks 1–2): Upon arrival, GAF Healthcare coordinates same-day or next-day specialist consultation with a dedicated Myeloma Program hematologist/oncologist. All diagnostic tests listed (bone marrow biopsy, FISH cytogenetics, PET-CT/WBCT, ECHO, PFTs, SPEP/IFE, sFLC, full biochemistry) are completed within 5–7 business days at the hospital. R-ISS staging is determined, transplant eligibility is formally assessed by a multidisciplinary tumor board (hematology, transplant physician, cardiology, nephrology), and a personalized treatment plan — including regimen selection (VRd vs. Dara-VRd), transplant timing, and maintenance strategy — is documented and shared with the patient in their preferred language.
PHASE 2 — INDUCTION CHEMOTHERAPY (Weeks 3–12, Outpatient-Based with Local Stay): VRd or Dara-VRd induction is administered over 3–4 cycles (each 21 days). Bortezomib injections are given at the day-care oncology unit (typically Days 1, 4, 8, 11 of each cycle, ~30 minutes per visit). Daratumumab SC injections are given weekly in Cycles 1–2, then every 2 weeks in Cycles 3–6 (infusion time: 3–5 minutes for SC formulation, or 4–6 hours for IV with premedications). Lenalidomide and Dexamethasone are taken orally at the patient's accommodation. GAF Healthcare arranges furnished apartments within 5–15 minutes of the hospital for the patient and one attendant. Response is assessed after Cycle 2 (interim response assessment) and after Cycle 4 (pre-transplant response assessment) using SPEP, sFLC, bone marrow biopsy, and PET-CT as indicated. Milestone: Achieving at least Partial Response (PR) — ideally VGPR or better — before proceeding to stem cell mobilization.
PHASE 3 — STEM CELL MOBILIZATION AND APHERESIS (Days 1–6 of Mobilization Phase): G-CSF injections are started. Daily CD34+ monitoring by blood flow cytometry begins on Day 4. Apheresis is performed on Day 5 or 6 (sometimes over 2 days if harvest is slow). Stem cells are cryopreserved in DMSO at -196°C in liquid nitrogen until transplant day. Plerixafor is added if CD34+ count in peripheral blood is <10–15 cells/µL on Day 4. Duration: approximately 5–7 days. The patient remains outpatient or in a hotel during mobilization; hospital admission for apheresis is typically 6–8 hours per session.
PHASE 4 — ASCT CONDITIONING AND TRANSPLANT HOSPITALIZATION (Days -3 to +21, Inpatient): The patient is admitted to the Bone Marrow Transplant (BMT) Unit — a HEPA-filtered, positive-pressure, reverse-isolation room. High-dose Melphalan is infused on Day -2 (or split over Days -3 and -2). Cryopreserved stem cells are thawed and reinfused on Day 0 (the 'transplant day' — typically a 15–30 minute procedure). The critical aplastic phase spans Days 0–14: the patient experiences severe fatigue, mucositis (oral ulceration, dysphagia — managed with regular oral cryotherapy, IV morphine PCA if needed, and nutritional support via IV or NG feeding), nausea/vomiting (managed with Ondansetron, Dexamethasone), and profound immunosuppression requiring strict infection control. Neutrophil engraftment is expected Days +10 to +14; platelet engraftment Days +12 to +18. The patient is discharged once: ANC >1.0 × 10⁹/L for 3 consecutive days, platelet >50 × 10⁹/L unsupported, afebrile for 48 hours, able to maintain oral hydration and nutrition, and Day 100 evaluation plan is in place. Total inpatient duration: approximately 21–28 days.
PHASE 5 — EARLY POST-TRANSPLANT RECOVERY (Days +21 to +100, Outpatient Local Stay): After discharge, the patient must remain within 30 minutes of the transplant center for the first 30–45 days post-discharge (Days +21 to Day +60). Outpatient visits are scheduled 2–3 times per week initially (CBC, biochemistry, clinical assessment). Key milestones: immune reconstitution (lymphocyte recovery by Day +30–60), resolution of mucositis and GI symptoms (by Week 3–4 post-ASCT), return of appetite and oral nutrition (Week 3–4), transition to maintenance therapy planning (Day +90–100). Pivotal Day +100 evaluation: bone marrow biopsy with MRD assessment, PET-CT, SPEP/IFE, sFLC — determines depth of response to ASCT and guides maintenance therapy selection. FIT-TO-FLY CRITERIA: Patients are cleared for international air travel at approximately Day +60 to +90 post-ASCT (8–12 weeks post-transplant), contingent upon: stable engraftment, ANC >1.0 × 10⁹/L, no active infection, platelet >75 × 10⁹/L, ability to manage medications independently, and confirmation that emergency care of equivalent standard is available at the home destination.
PHASE 6 — LONG-TERM MAINTENANCE AND REMOTE FOLLOW-UP (Months 3 Onward): Lenalidomide maintenance (or VR for high-risk) is initiated post-Day +100 evaluation. GAF Healthcare facilitates telemedicine follow-up with the treating hematologist for remote patients. Surveillance protocol includes: monthly CBC and biochemistry, quarterly SPEP/IFE and sFLC, semi-annual bone marrow biopsy with MRD assessment, and annual PET-CT or WBCT. Relapse monitoring is based on IMWG response criteria; any biochemical relapse triggers immediate re-engagement with the treatment team. Vaccination schedule (inactivated vaccines only for 12 months post-ASCT; live vaccines contraindicated for minimum 24 months) is coordinated with the patient's home physician.
Risks & Considerations
Multiple Myeloma treatment with VRd, ASCT, and Daratumumab carries a spectrum of procedure-specific and drug-specific risks that patients must understand prior to initiating therapy. ASCT-related mortality at experienced high-volume centers is now <1–2% (Treatment-Related Mortality, TRM), but the procedure carries significant morbidity during the aplastic phase. Bortezomib (Velcade) causes peripheral neuropathy in up to 30–40% of patients (reduced to ~6% with subcutaneous administration); Grade 3–4 neuropathy necessitating dose reduction or discontinuation occurs in ~8–10%. Lenalidomide (Revlimid) carries a significant risk of venous thromboembolism (DVT/PE) — mandatory thromboprophylaxis with aspirin, LMWH, or warfarin (based on individual risk score: IMWG VTE risk score) is required throughout therapy. Lenalidomide is strictly teratogenic (Category X) and is absolutely contraindicated in pregnancy; all patients of childbearing potential must adhere to mandatory contraception programs (dual contraception for females; condom use for males). Daratumumab causes infusion-related reactions (IRR) in up to 40–50% of patients with IV administration, predominantly during the first infusion; IRR rates drop to <10% with the subcutaneous formulation. Daratumumab interferes with blood bank crossmatching by binding CD38 on red blood cells — blood banks must be pre-notified and perform DTT (dithiothreitol) treatment of donor cells or use genotyping-based crossmatch. During ASCT, high-dose Melphalan causes severe oral and GI mucositis (Grade 3–4 in up to 60% of patients), febrile neutropenia (nearly universal, requiring broad-spectrum antibiotics), hemorrhagic cystitis (prevented by IV hydration and Mesna), and prolonged severe fatigue. Pulmonary complications (Idiopathic Pneumonia Syndrome, IPS) occur in 2–5% post-ASCT and carry significant mortality. Secondary malignancies — particularly Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) — represent a long-term risk of prior cytotoxic and alkylating agent exposure, with a cumulative incidence of approximately 2–3% at 10 years. Patients with renal impairment require careful dose adjustment of renally-cleared agents (Bortezomib can often be given at full dose; Lenalidomide requires significant renal dosing adjustments based on CrCl). High-risk cytogenetic patients (del17p, gain 1q21) have intrinsically poorer prognoses despite optimal therapy and should be counseled about realistic expectations, potential clinical trial enrollment, and consideration of allogeneic SCT in eligible cases.
Top Hospitals for Multiple Myeloma Treatment
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Tata Memorial Hospital
Mumbai, India
Manipal Hospitals Dwarka
New Delhi, India
Burjeel Hospital for Advanced Surgery Dubai
Dubai, UAE
Top Doctors for Multiple Myeloma Treatment
Internationally trained specialists in Hematology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Rahul Bhargava
MBBS, MD (General Medicine), DM (Clinical Hematology), Advanced Fellowship in Unrelated and Haploidentical Transplant
Hematologist & BMT Specialist
Fortis Memorial Research Institute, Gurgaon, India
20+ Yearsof experience
Dr. Rahul Bhargava is a leading Hematologist and BMT specialist currently working at Fortis Memorial Research Institute, Gurugram. With an experience of more than 20 years in Hematology, Pediatric Hemato-Oncology, and Bone Marrow Transplantation, he has performed numerous BMTs with consistently successful outcomes and is widely regarded as one of the most trusted names in this highly specialised field in India. He primarily specialises in haploidentical… Read more
Dr. Vikas Dua
MBBS, MD (Paediatrics), FNB (Paediatric Hematology Oncology), Fellowship in Paediatric Bone Marrow Transplant, Outreach Programme in Paediatric BMT
Pediatric Hematologist & BMT Specialist
Fortis Memorial Research Institute, Gurgaon, India
20+ Yearsof experience
Dr. Vikas Dua is one of the leading paediatric hemato-oncologists and bone marrow transplant specialists of his generation. He currently serves as Principal Director & Head — Paediatric Haematology, Haemato-Oncology and Bone Marrow Transplant at Fortis Memorial Research Institute, Gurgaon. Dr. Dua and his team have performed more than 1,200 transplants, with outcomes among the best in the field of paediatric haematology, oncology and BMT. He is… Read more
Dr. Amita Mahajan
MBBS, MD (Pediatrics), MRCPCH, CCST (Advanced Training in Pediatric Oncology)
Pediatric Hematologist and Oncologist
Indraprastha Apollo Hospital, New Delhi, India
32+ Yearsof experience
Dr. Amita Mahajan is a Senior Consultant in Pediatric Hematology and Oncology at Indraprastha Apollo Hospital, New Delhi, with over 32 years of dedicated clinical experience in childhood blood disorders and cancers. She completed her MBBS and MD in Pediatrics from the All India Institute of Medical Sciences (AIIMS), New Delhi, followed by advanced international training: the MRCPCH from the Royal College of Paediatrics and Child Health, London, and… Read more
Dr. Govind Eriat
MBBS, DNB, FRCP, Fellowship in Leukemia/BMT
Hematologist & Hemato-Oncologist
Gleneagles Hospitals, Bengaluru, India
14+ Yearsof experience
Dr. Govind Eriat is a Visiting Consultant in Hematology and Hemato-Oncology at Gleneagles Hospitals, Bengaluru, bringing over 14 years of specialized clinical experience in blood disorders and cancer care. He holds an MBBS degree and has completed his DNB in Internal Medicine, establishing a strong foundation in comprehensive patient care. His international credentials include Fellowship from the Royal College of Physicians (FRCP), United Kingdom, and a… Read more
Dr. K. Karuna Kumar
MD, DNB Clinical Hematology
Hematologist
Yashoda Hospitals, Secunderabad, Hyderabad, India
18+ Yearsof experience
Dr. K. Karuna Kumar is a Clinical Consultant in Hematology with over 18 years of specialised clinical experience. He holds an MD from Nizam's Institute of Medical Sciences (NIMS), Hyderabad, and a DNB in Clinical Hematology from Narayana Hrudayalaya, Bangalore—two of India's most prestigious medical institutions. His training has equipped him with exceptional expertise in both benign and malignant blood disorders, as well as complex transplant procedures.… Read more
Frequently Asked Questions — Multiple Myeloma Treatment
The total cost of a complete Multiple Myeloma treatment episode — including VRd or Dara-VRd induction chemotherapy, peripheral blood stem cell mobilization and apheresis, high-dose Melphalan conditioning, Autologous Stem Cell Transplantation (ASCT), BMT unit hospitalization, supportive medications, and standard post-transplant monitoring — ranges from approximately USD 18,000 to USD 45,000 in India, depending on the specific regimen (VRd vs. quadruplet Dara-VRd), the number of induction cycles, response assessments required, and any complications during the ASCT phase. The same treatment in the UAE (Dubai or Abu Dhabi) costs approximately USD 45,000 to USD 95,000, reflecting premium hospital infrastructure, higher drug acquisition costs for imported branded biologics (Daratumumab branded as Darzalex is significantly more expensive in the UAE than in India, where domestic pricing controls and biosimilar availability reduce costs substantially), and higher facility overheads. India offers 50–65% cost savings while maintaining equivalent clinical outcomes at JCI and NABH-accredited transplant centers performing hundreds of ASCTs annually. The UAE offers premium-tier facilities with DHA and JCI accreditation, particularly advantageous for patients from GCC countries who prefer proximity, Arabic-language services, and luxury clinical environments. GAF Healthcare provides detailed cost projections for each individual patient after reviewing their diagnostic reports and proposed treatment plan, ensuring full cost transparency before any commitment.
The required in-country stay depends on which phase of treatment is being undertaken. For patients receiving induction chemotherapy only (VRd or Dara-VRd without ASCT — applicable to transplant-ineligible patients or those deferring transplant), a minimum stay of 4–6 weeks is required to complete the first 2 induction cycles and confirm initial response and tolerability, after which the patient may return home and continue maintenance therapy locally with remote follow-up via GAF Healthcare's telemedicine service. For patients undergoing the full VRd induction + ASCT pathway, the total mandatory in-country stay is significantly longer: approximately 10–14 weeks (approximately 2.5 to 3.5 months). This breaks down as: 6–8 weeks for induction chemotherapy (outpatient, local stay required), 1 week for stem cell mobilization and apheresis, 3–4 weeks of inpatient hospitalization for ASCT conditioning and engraftment, and a further 4–6 weeks of post-ASCT outpatient monitoring before fit-to-fly clearance is granted. Patients are declared fit to fly at approximately Day +60 to Day +90 post-ASCT, provided the following criteria are met: stable neutrophil engraftment (ANC >1.0 × 10⁹/L), platelet count >75 × 10⁹/L without transfusion support, no active infection or fever, resolution of significant mucositis and GI complications, ability to self-administer oral medications, and availability of an equivalent standard of emergency hematological care at the home destination. Long-haul flights with prolonged immobility carry a VTE risk — LMWH prophylaxis for flights exceeding 4 hours is routinely recommended for all myeloma and post-ASCT patients. GAF Healthcare's medical coordinator manages all fit-to-fly certifications, airline communication for medical assistance requirements, and coordination with the home country physician for seamless handover.
Multiple Myeloma response rates and long-term outcomes have improved dramatically over the past decade with modern triplet and quadruplet regimens. The key outcome benchmarks at high-volume centers in India and the UAE are as follows: With VRd induction (3–4 cycles), approximately 70–80% of patients achieve at least a Very Good Partial Response (VGPR), and 30–45% achieve a stringent Complete Response (sCR) or Complete Response (CR) before transplant. The addition of Daratumumab (Dara-VRd quadruplet) increases pre-transplant MRD negativity rates to approximately 70–75% (vs. 45–50% with VRd alone), as demonstrated in the PERSEUS trial (2024), representing a landmark improvement in response depth. Following ASCT with high-dose Melphalan conditioning, post-transplant sCR/CR rates reach 60–70% in patients who responded well to induction. With Lenalidomide maintenance post-ASCT, the median Progression-Free Survival (PFS) is approximately 54–66 months (4.5–5.5 years) in standard-risk patients, and 5-year Overall Survival (OS) is 55–65% across all risk groups. For standard-risk patients (no high-risk cytogenetics), 5-year OS exceeds 70–75%. For transplant-ineligible patients on Dara-Rd (MAIA trial), median PFS reached 61.9 months with OS rates of approximately 66.3% at 5 years. It is important to note that Multiple Myeloma remains an incurable disease for the vast majority of patients with current technology, but it is highly treatable and controllable, with many patients living 10+ years with excellent quality of life on sequential therapies. Patients with high-risk cytogenetics — particularly del(17p) or gain(1q21) — have shorter median PFS (typically 24–36 months) and should be counseled about clinical trial options, tandem ASCT, or early consideration of CAR-T cell therapy or bispecific antibodies at relapse. GAF Healthcare only works with centers that report outcomes aligned with or exceeding international EBMT and CIBMTR benchmarks.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive end-to-end non-medical support designed specifically for the complexities of a prolonged oncology treatment journey involving multiple hospital phases, outpatient cycles, and extended country stays.
VISA AND ENTRY FACILITATION: For India: GAF Healthcare's dedicated visa coordination team assists patients in obtaining an e-Medical Visa (e-MV), which allows a stay of up to 60 days per visit with two extensions available (total up to 180 days), and permits one accompanying attendant on an e-Medical Attendant Visa (e-MAV). Given that a full VRd induction + ASCT journey spans 10–14 weeks, GAF coordinates timely visa extension applications with the Foreigners Regional Registration Office (FRRO) and the hospital's international patient department. For the UAE (Dubai and Abu Dhabi): Citizens of over 90 countries — including all GCC nationals, EU/UK/US/Canada/Australia citizens — receive visa-on-arrival or visa-free entry. Patients from countries requiring advance visas receive support through GAF Healthcare's UAE visa assistance service, with a standard 30-day tourist visa extendable to 60 days, or a Medical Treatment Visa for extended stays coordinated with the Dubai Health Authority (DHA) or Department of Health Abu Dhabi (DoH).
AIRPORT AND GROUND TRANSFERS: GAF Healthcare provides 24/7 airport reception with a patient transport coordinator holding a personalized nameplate. All vehicles are air-conditioned, wheelchair-accessible where required, and for post-ASCT or immunocompromised patients, sanitized medical-grade vehicles are available. All transfers between accommodation and the hospital for every clinical appointment — including early-morning apheresis sessions, daily Bortezomib visits, and emergency presentations — are arranged and tracked by the GAF patient coordinator.
ACCOMMODATION FOR PATIENT AND ATTENDANT: GAF Healthcare partners with fully furnished serviced apartments and patient-friendly hotels within 5–15 minutes of the treating hospital. Accommodation is equipped with kitchen facilities (supporting dietary requirements during mucositis recovery and immune reconstitution), high-speed WiFi, 24-hour security, housekeeping, and, where required, in-home nursing support through GAF's partner home care network. Attendant accommodation is arranged at concessional rates negotiated by GAF Healthcare, and caregiver training sessions (medication management, infection prevention, feeding support) are organized in collaboration with the hospital's transplant nursing team.
DEDICATED MEDICAL COORDINATOR AND TRANSLATION: Every GAF Healthcare patient is assigned a dedicated bilingual Medical Coordinator who speaks the patient's native language (available in Arabic, Russian, French, Swahili, Bengali, Amharic, and others) and serves as the single point of contact throughout the treatment journey. The coordinator attends all major consultations, facilitates real-time interpretation, transcribes treatment summaries in the patient's preferred language, liaises between the patient and the clinical team for scheduling changes or emergencies, and provides psychological and logistical support during the demanding ASCT hospitalization phase.
TELEMEDICINE AND POST-DEPARTURE FOLLOW-UP: Upon return home, GAF Healthcare facilitates secure telemedicine consultations between the patient and their treating hematologist at regular intervals aligned with the maintenance monitoring schedule. Comprehensive medical records — including bone marrow biopsy reports, FISH cytogenetics, SPEP/sFLC trend data, MRD results, and discharge summaries — are translated, compiled in a structured digital patient file, and shared with the patient's home physician to ensure seamless continuity of care. GAF's medical team remains accessible for urgent second opinions and emergency re-referral if relapse is suspected.
Patients Also Explore
Other treatments commonly sought by patients considering Multiple Myeloma Treatment.
Breast Cancer Treatment
Cancer Care
Lung Cancer Treatment
Cancer Care
Liver Transplant
Transplant
Lung Transplant
Transplant